Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors

Journal of Chemical Information and Computer Sciences

Volumn 38, Issue 4, 1998, Pages 761-767

  Debnath, Asim Kumar ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; PROTEINASE INHIBITOR; UREA;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG SCREENING; HUMAN; IN VITRO STUDY; METHODOLOGY; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HIV PROTEASE INHIBITORS; HUMANS; MODELS, MOLECULAR; REGRESSION ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; UREA;

EID: 0032109496     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci980014c     Document Type: Article

References (32)

1. Kohl, N. E.; Emini, E. A.; Scheif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnik, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
2. Debouck, C. The HIV-1 Protease as a Therapeutic Target for AIDS. AIDS Res. Hum. Retroviruses. 1992, 153-164.
3. McQuade, T. J.; Tomasselli, A. G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T. K.; Heinrikson, R. L.; Tarpley, W. G. A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrest HIV-like Particle Maturation. Science 1990, 247, 454-456.
4. Meek, T. D.; Lambert, D. M.; Dreyer, G. B.; Carr, T. J.; Tomaszek, T. A. Jr.; Moore, M. L.; Strickler, J. E.; Debouck, C.; Hyland, L. J.; Mathews, T. J.; et al. Inhibition of HIV-1 Protease in Infected T-lymphocytes by Synthetic Peptide Analogues. Nature 1990, 343, 90-92.
5. Winslow, D. L.; Otto, M. J. HIV Protease Inhibitors. AIDS 1995, Suppl A:S183-S192.
6. Prasad, J. V.; Lunney, E. A.; Para, K. S.; Tummino, P. J.; Ferguson, D.; Hupe, D.; Domagala, J. M.; Erickson, J. W. Nonpeptide Potent HIV-1 Protease Inhibitors. Drug Des. Discov. 1996, 13, 15-28.
7. Deeks, S. G.; Volderding, P. A. HIV-1 Protease Inhibitors. AIDS Clin. Rev. 1997, 145-185.
8. Korant, B. D.; Rizzo, C. J. The HIV Protease and Therapies for AIDS. Adv. Exp. Med. Biol. 1997, 421, 279-284.
9. Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J. O. HIV-1 Protease Inhibitors: A Review for Clinicians. JAMA 1997, 277, 145-153.
10. Jadav, P. K.; Ala, P.; Woerner, F. J.; Chang, C.-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against both Wild-Type and Protease Inhibitor Resistant Mutants of HIV. J. Med. Chem. 1997, 40, 181-191 (references therein).
11. Ridky, T.; Leis, J. Development of Drug Resistance to HIV-1 Protease Inhibitors. J. Biol. Chem. 1995, 270, 29621-29623.
12. Appelt, K. Crystal Structures of HIV-1 Protease-Inhibitor Complexes. Perspect. Drug Discovery Design 1993, 1, 23-48.
13. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F. Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.
14. Wilkerson, W. W.; Akamike, E.; Cheatham, W. W.; Hollis, A. Y.; Collins, R. D.; DeLucca, I.; Lam, P. Y. S.; Ru, Y. HIV Protease Inhibitory bis-Benzamide Cyclic Urea: A Quantitative Structure - Activity Relationship Analysis. J. Med. Chem. 1996, 39, 4299-4312.
15. Wilkerson, W. W.; Dax, S.; Cheatham, W. W. Nonsymmetrically Substituted Cyclic Urea HIV Protease Inhibitors. J. Med. Chem. 1997, 40, 4079-4088.
16. Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A. CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160.
17. Oprea, T. I.; Waller, C. L.; Marshall, G. R. Three-Dimensional Quantitative Structure-Activity Relationship of Human Immunodeficiency Virus (I) Protease Inhibitors. 2. Predictive Power Using Limited Exploration of Alternate Binding Modes. J. Med. Chem. 1994, 37, 2206-2215.
18. Oprea, T. I.; Waller, C. L.; Marshall, G. R. 3D-QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. III. Interpretation of CoMFA Results. Drug Des. Discov. 1994, 12, 29-51.
19. Wei, D. T.; Meadows, J. C.; Kellogg, G. E. Effects of Entropy on QSAR Equation for HIV-1 Protease: 1. Using Hydropathic Binding Descriptors. 2. Unrestrained Complex Structure Optimizations. Med. Chem. Res. 1997, 7, 259-270.
20. SYBYL Molecular Modeling System (Version 6.4) available from Tripos Associates Inc., 1699 South Hanley Road, St. Louis, MO 63144.
21. Dewar, M. J. S.; Zoelbisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
22. Clark, M.; Cramer, III, R. D.; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
23. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W. J. The Covariance Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses. SIAM J. Sci. Stat. Comput. 1994, 5, 735-743.
24. Folker, G.; Merz, A.; Rognan, D. CoMFA: Scope and Limitations. In 3D QSAR in Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; Escom: Leiden, 1993, p 583.
25. Cramer, R. D. III; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
26. Corelli, F.; Manetti, F.; Tafi, A.; Campiani, G.; Nacci, V.; Botta, M. Dilitiazem-like Calcium Entry Blockers: A Hypothesis of the Receptor-binding Site Based on a Comparative Molecular Field Analysis Model. J. Med. Chem. 1997, 40, 125-131.
27. Kim, K. H. Description of an Electrostatic Nonlinear Relationship in Comparative Molecular Field Analysis. Med. Chem. Res. 1997, 7, 45-52.
28. Kaminski, J. J.; Doweyko; A. M. Antiulcer Agents. 6. Analysis of the in vitro Biochemical and in vivo Gastric Antisecretory Activity of substituted imidazol[1,2-a]pyridines and Related Analogues Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies. J. Med. Chem. 1997, 40, 427-436.
29. Cho, S. J.; Serrano Gracia, M. L.; Bier, J.; Tropsha, A. Structure-based Alignment and Comparative Molecular Field Analysis of Acetylcholinesterase Inhibitors. J. Med. Chem. 1996, 39, 5064-5071.
30. Steinmetz, W. E. A CoMFA Analysis of Selected Physical Properties of Amino Acids in Water. QSAR 1995, 14, 19-23.
31. Debnath, A. K.; Jiang, S.; Strick, N.; Lin, K.; Haberfield, P.; Neurath, A. R. Three-Dimensional Structure-Activity Analysis of a Series of Porphyrin Derivatives with Anti-HIV-1 Activity Targeted to the V3 Loop of the gp120 Envelope Glycoprotein of the Human Immunodeficiency Virus type 1. J. Med. Chem. 1994, 37, 1099-1108.
32. Martin, Y. C.; Lin, C. T.; Wu, J. Application of CoMFA to D1 Dopaminergic Agonists: A Case Study. In 3D QSAR in Drug Design: Theory Methods and Applications: Kubinyi, H., Ed., ESCOM, Leiden, 1993, p 643.